Clozapine
FDA-approved product (tablet, oral), marketed as Clozapine, Clozaril, Fazaclo Odt and 1 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Psychosis
- Schizoaffective disorder
- Schizophrenia
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Diazepines, oxazepines, thiazepines and oxepines
- FDA pharmacologic class
- Atypical Antipsychotic FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA42.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli48.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae19.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis63.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Clozapine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Levocabastine HydrochlorideExisting use: Eye allergy, Nasal congestion49.5% AI-predicted activityagainst E. coli5 registered studies
- SaquinavirExisting use: HIV infection, HIV-1 infection, Viral disease49.4% AI-predicted activityagainst E. coli50+ registered studies
- Ibrexafungerp CitrateExisting use: Vulvovaginal candidiasis49.4% AI-predicted activityagainst E. coliNo documented evidence found
- Mobocertinib SuccinateExisting use: Neoplasm, Non-small cell lung carcinoma49.2% AI-predicted activityagainst E. coliNo documented evidence found
- SparsentanExisting use: IGA glomerulonephritis49.2% AI-predicted activityagainst E. coli11 registered studies
- Epinastine HydrochlorideExisting use: Allergic conjunctivitis, Allergic disease, Eye allergy49.0% AI-predicted activityagainst E. coli10 registered studies
- Omidenepag IsopropylExisting use: Ocular hypertension, Open-angle glaucoma49.0% AI-predicted activityagainst E. coli1 registered study
- LesinuradExisting use: Gout, Hyperuricemia49.0% AI-predicted activityagainst E. coli22 registered studies
- Imatinib MesylateExisting use: Acute lymphoblastic leukemia, B-cell acute lymphoblastic leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and 7 more48.9% AI-predicted activityagainst E. coli50+ registered studies
- Prucalopride SuccinateExisting use: Constipation, Constipation disorder48.9% AI-predicted activityagainst E. coli7 registered studies
- FamciclovirExisting use: Eye infection, Genital herpes, Herpes Labialis and 3 more48.8% AI-predicted activityagainst E. coli25 registered studies
- AbemaciclibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 3 more48.7% AI-predicted activityagainst E. coli50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
CARE Study: Improving Treatment for the Most Severely Ill With Schizophrenia
NCT00272584 · start 2001-06
Registered record
- Registry ID
- NCT00272584
- Conditions
- Psychosis, Schizophrenia
- Interventions
- Risperidone
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2001-06
- Completion
- 2004-01
- Enrolment
- 100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPsychosis, SchizophreniaInterventionRisperidonePhasePhase 4Registry statusCompletedCATIE- Schizophrenia Trial
NCT00014001 · start 2000-12
Registered record
- Registry ID
- NCT00014001
- Conditions
- Schizophrenia
- Interventions
- perphenazine; olanzapine; quetiapine; risperidone; ziprasidone; clozapine; fluphenazine decanoate
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2000-12
- Completion
- 2004-12
- Enrolment
- 1,600
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSchizophreniaInterventionperphenazine; olanzapine; quetiapine; risperidone +3 morePhasePhase 4Registry statusCompletedElectroconvulsive Therapy in Clozapine Refractory Schizophrenia
NCT00042224 · start 2000-12
Registered record
- Registry ID
- NCT00042224
- Conditions
- Schizophrenia
- Interventions
- Electroconvulsive Therapy (ECT); Clozapine
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Completed
- Start
- 2000-12
- Completion
- 2008-07
- Enrolment
- 39
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSchizophreniaInterventionElectroconvulsive Therapy (ECT); ClozapinePhasePhase 1 / Phase 2Registry statusCompletedStudy of Clozapine for the Treatment of Psychosis in Patients With Idiopathic Parkinson's Disease
NCT00004826 · start 1993-10
Registered record
- Registry ID
- NCT00004826
- Conditions
- Parkinson Disease
- Interventions
- clozapine
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 1993-10
- Completion
- 1997-11
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionParkinson DiseaseInterventionclozapinePhaseNot applicableRegistry statusCompletedFazaClo Outcomes in the Control of Schizophrenia (FOCUS) Study Survey
NCT00683891
Registered record
- Registry ID
- NCT00683891
- Conditions
- Weight Gain; Sialorrhea
- Interventions
- FazaClo (clozapine, USP) ODT
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionWeight Gain; SialorrheaInterventionFazaClo (clozapine, USP) ODTPhaseNot recordedRegistry statusCompleted